Showing results (21-30 of 529) with videos related to

Sort By:
Pageof 53
European Heart Journal. Cardiovascular Pharmacotherapy|August 10, 2021
Oral antithrombotic therapy for the prevention of recurrent cerebrovascular eventsDavide Capodanno, Dominick J Angiolillo
European Heart Journal. Cardiovascular Pharmacotherapy|June 20, 2020
Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trialsAyman Elbadawi, Mina Shnoda, Karim Mahmoud, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|September 22, 2022
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rateGabriel S Costa, Letícia S Julião-Silva, Vinícius S Belo, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2021
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48Marc P Bonaca, Elliott M Antman, Jonathan W Cunningham, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 31, 2018
Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerationsJonas Hallén, Nadarajah Sreeharan
European Heart Journal. Cardiovascular Pharmacotherapy|July 28, 2018
Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapyTero Penttilä, Mika Lehto, Jussi Niiranen, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 7, 2021
Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trialsAntonio Abbate, George F Wohlford, Marco Giuseppe Del Buono, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 25, 2022
Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinical Practice Research DatalinkBrenda N Baak, Susan S Jick
European Heart Journal. Cardiovascular Pharmacotherapy|October 11, 2019
Resistant hypertension: new insights and therapeutic perspectivesLuis M Ruilope, Elena Rodríguez-Sánchez, José Alberto Navarro-García, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|July 6, 2019
Antithrombotic treatment and major adverse cardiac events after bleeding in patients with myocardial infarction: a retrospective analysis of nationwide registry dataHafsah Nabi, Rasmus Rørth, Daniel H Tajchman, et al.
Pageof 53